新型吲哚咔唑化合物的合成与抗肿瘤活性

设计合成了一系列吲哚咔唑结构的抗肿瘤新化合物. 通过对反应溶剂进行选择和调整, 优化了吲哚咔唑母核合成的反应条件, 使后处理更为简便. 用溴化噻唑蓝四氮唑(MTT)法对所合成的9个目标化合物进行了体外细胞毒活性测试, 结果表明, 化合物4a, 4b, 4d, 4f和4i对人结肠癌HCT116和鼠白血病P388细胞的活性均强于阳性对照ED-571, 其中化合物4f对P388细胞的活性是阳性对照的10倍.     

18β-甘草次酸吡啶酰胺衍生物的定向合成及其初步抗癌活性研究

以18β-甘草次酸和2,5-吡啶二甲酸为起始原料,便捷地合成了5种含吡啶杂环多酰胺结构的18β-甘草次酸衍生物.全部新合成化合物的结构由1H NMR,13C NMR及HRMS等方法得到了确证.通过四甲基偶氮唑盐(MTT)法对所有新合成化合物的抑制人宫颈癌Hela细胞活性进行了体外评价,初步发现目标系列化合物对人宫颈癌Hela细胞均具有细胞毒活性,能够有效抑制Hela细胞增殖、诱导其凋亡,IC50最小值仅为0.02μmol·L-1,均优于临床抗肿瘤药物阿糖胞苷.     

新型青蒿砜-酯类衍生物的合成及其抗癌活性研究

以双氢青蒿素为起始原料,经胺化、氧化、烷基化、酯化反应,快速、高效地合成了一系列青蒿砜系列衍生物,目标化合物的结构通过IR、1H NMR、13C NMR和HRMS得到了确证;以四甲基偶氮唑盐比色法(MTT法),研究了该类化合物对人肝癌细胞株SMMC-7721的抗癌活性.初步研究结果表明,该类化合物具有明显地抑制人肝癌细胞增殖、诱导其凋亡的细胞活性,给药72 h,半数抑制浓度IC50最优值为0.06μmol/L.同时采用Annexin/PI流式细胞分析法检测化合物7b对人肝癌细胞SMMC-7721的凋亡情况,结果显示实验组与正常对照组相比人肝癌细胞早期凋亡率和总凋亡率均显著增加.在与青蒿素、双氢青蒿素(DHA)和青蒿砜的对比实验中发现,该类化合物的抗肿瘤活性明显提高,表现出了该类化合物在抗癌药物开发方面具有潜在的应用价值.     

基于二硫代氨基甲酸酯活性亚结构的先导优化及其抗增殖活性（英文）

设计了一系列含喹唑啉酮、苯并噁嗪酮和香豆素单元的二硫代氨基甲酸酯(DTC)衍生物.基于收率高、反应时间短、条件温和易于后处理的三组分一锅法反应,可高效构建目标化合物库.采用四甲基偶氮唑盐(MTT法)测试了目标化合物对人肝癌细胞HCCLM-7、人宫颈癌细胞Hela、人乳腺癌细胞MDA-MB-435S、人结肠癌细胞SW-480、人喉癌细胞Hep-2和人乳腺癌细胞MCF-7等6种肿瘤细胞株的体外抗增殖活性.结果表明,3个化合物表现出高效和广谱的抗增殖活性(IC_(50):3.5~13.5μmol·L~(-1)).部分化合物的活性较阳性对照药5-氟尿嘧啶(5-FU)提高了10倍以上(IC_(50):8.1~128.7μmol·L~(-1)).以上结果表明,含稠杂环单元的二硫代氨基甲酸酯(DTC)衍生物是一类有价值的抗肿瘤活性先导结构.     

N9位芳基取代嘌呤-8-酮类衍生物的合成及抗肿瘤活性

合成了一系列N9位芳基取代嘌呤-8-酮类衍生物, 利用核磁共振氢谱(¹H NMR)、 核磁共振碳谱(¹³C NMR)和高分辨质谱(HRMS)进行了结构确证. 采用四甲基偶氮唑盐(MTT)法测定了目标化合物的体外抗肿瘤细胞增殖活性. 结果表明, 嘌呤酮环的C2位及N9位的取代对活性有较大影响, C2位引入对位由含氮六元环取代的苯胺, N9位引入对三氟甲基苯均有利于提高抗肿瘤活性. 化合物12c对人白血病细胞(K562)、 人前列腺癌细胞(PC-3)、 人乳腺癌细胞(MDA-MB-231)及人结肠癌细胞(HCT116)的抑制效果明显优于阳性对照药R-Roscovitine.     

4-(5H-嘧啶并[5,4-b]吲哚-2-基-氨基)苯甲酰胺类化合物的设计、合成及抗肿瘤活性研究

设计、合成了19个未见文献报道的4-(5H-嘧啶并[5,4-b]吲哚-2-基-氨基)苯甲酰胺类衍生物,所有化合物结构均经~1H NMR、~(13)C NMR及HRMS确认。采用噻唑蓝(MTT)法测试了目标化合物对人结肠癌细胞(HCT116)、人乳腺癌细胞(MD-MBA-231)、大鼠神经胶质瘤细胞(C6)、人非小细胞肺癌细胞(A549)、人乳腺癌细胞(MCF-7)的体外抗肿瘤活性。所有化合物均表现出较好的抗肿瘤活性,其中5a、5b、5c、5e、5i、5p和5r对多个细胞株的抑制活性为阳性对照药品5-氟尿嘧啶的20～100倍;其中,以5b的抗肿瘤活性最为突出,对肿瘤细胞HCT116、MD-MBA-231、C6、A549、MCF-7的IC_(50)分别为3. 26、3. 06、0. 63、0. 68、2. 32μmol/L。初步研究结果表明,此类化合物对肿瘤细胞增殖有明显抑制作用,为新型抗肿瘤化合物的设计、合成提供了思路。     

3-epi-Jaspine B类似物的合成和抗肿瘤活性评价

Jaspine B是从海绵中提取的具有显著肿瘤活性的天然产物.为了寻找活性更好,合成方法更简洁的抗肿瘤化合物,设计并合成了一系列3-epi-Jaspine B类似物,共16个化合物,所合成的化合物均未见文献报道.所有化合物都经过~1H NMR、~(13)C NMR和HRMS确定分子结构.对所合成的化合物用噻唑蓝(MTT)法对4种肿瘤细胞(B16-F10小鼠皮肤黑色素瘤细胞、A-549人肺癌细胞、MCF-7人乳腺癌细胞、PC-3人前列腺癌细胞)进行生物活性测试,部分化合物对肿瘤细胞有抑制作用,其中化合物8f和11对A-549人肺癌细胞具有较好的活性,其IC_(50)分别为(9.646±0.984)和(7.144±0.854)μg/m L.     

靛红杂合喹唑啉类化合物的合成及抗肿瘤活性研究

合成了9种靛红杂合的喹唑啉类目标化合物,借助NMR、IR和HRMS对目标化合物进行了结构表征,并通过晶体的培养及X射线衍射数据进一步确定了目标化合物的结构.同时采用噻唑蓝(MTT)法在人结直肠癌细胞SW480、人非小细胞肺癌细胞A549和NCI-H1975、人表皮鳞癌细胞A431上对这些化合物进行了抗肿瘤活性的初步体外评价.结果表明,大部分目标化合物具有明显的抑制肿瘤细胞增殖的作用,尤其是化合物(E)-3-(((E)-(5-(4-(3-乙炔苯胺基)喹唑啉-6-基)呋喃-2-基)亚甲基)亚肼基)吲哚啉-2-酮(4a),在4种所试肿瘤细胞上均表现出良好的抑制肿瘤细胞增殖的作用,其效果优于临床使用的抗肿瘤药物拉帕替尼.     

4-(5H-嘧啶并[5,4-b]吲哚-2-基-氨基)苯甲酰胺类化合物的设计、合成及抗肿瘤活性研究

设计、合成了19个未见文献报道的4-(5H-嘧啶并[5,4-b]吲哚-2-基-氨基)苯甲酰胺类衍生物,所有化合物结构均经~1H NMR、~(13)C NMR及HRMS确认。采用噻唑蓝(MTT)法测试了目标化合物对人结肠癌细胞(HCT116)、人乳腺癌细胞(MD-MBA-231)、大鼠神经胶质瘤细胞(C6)、人非小细胞肺癌细胞(A549)、人乳腺癌细胞(MCF-7)的体外抗肿瘤活性。所有化合物均表现出较好的抗肿瘤活性,其中5a、5b、5c、5e、5i、5p和5r对多个细胞株的抑制活性为阳性对照药品5-氟尿嘧啶的20～100倍;其中,以5b的抗肿瘤活性最为突出,对肿瘤细胞HCT116、MD-MBA-231、C6、A549、MCF-7的IC_(50)分别为3. 26、3. 06、0. 63、0. 68、2. 32μmol/L。初步研究结果表明,此类化合物对肿瘤细胞增殖有明显抑制作用,为新型抗肿瘤化合物的设计、合成提供了思路。     

鱼藤中抗肿瘤活性化合物的追踪分离及与DNA的相互作用

采用活性追踪分离的方法, 从鱼藤中分离鉴定出了2个抗肿瘤活性化合物, 即羟基鱼藤素(1)和鱼藤酮(2). 用丽丝胺罗丹明B(SRB)法评价其抗肿瘤活性, 用紫外光谱和荧光光谱等方法探讨了化合物与DNA的相互作用. 结果发现, 羟基鱼藤素(1)与鱼藤酮(2)为鱼藤的抗肿瘤活性成分, 对人大肠癌细胞HCT8、人肝癌细胞BEL7402、人胃癌细胞BGC823、人肺癌细胞A549和人卵巢癌细胞A2780的半数抑制浓度(IC₅₀) 在0.1~90.0 μmol/L之间. 这两种化合物的紫外吸收强度随着HS-DNA的加入均呈现减色效应, 并使EB-HS-DNA复合体系荧光强度减弱, 表明化合物的抗肿瘤活性与DNA以插入方式作用有关.     

8-黄酮哌嗪衍生物的合成及生理活性研究

设计合成了4个8-黄酮甲基哌嗪和4个8-黄酮甲基多聚异戊二烯哌嗪类化合物, 产物结构均经1H NMR, ESI-MS和元素分析确认. 使用MTT法测试了8个化合物对Bel-7402 (人肝癌细胞)和K562(白血病细胞)两种肿瘤细胞的体外抗肿瘤活性. 结果表明哌嗪单黄酮和双黄酮体外生理活性并不理想, 但在黄酮骨架上引入多聚异戊二烯哌嗪基后的产物对K562细胞表现出比N,N-二(8-黄酮甲基)香叶基胺(1)更好的体外抗肿瘤活性.     

Kadcoccilactones K-R, triterpenoids from Kadsura coccinea

Phytochemical investigation on the stems of Kadsura coccinea led to the isolation of 8 new triterpenoids, kadcoccilactones K-R (1-8), and 10 known analogues. Their structures were elucidated on the basis of extensive spectroscopic analysis. Compounds 1-3 characterized with an aromatic ring E in their molecules are rarely naturally occurred kadlongilactone derivatives. Moreover, all compounds were evaluated for their inhibitory activity against K562, Bel-7402, and A549 human tumor cells. Compounds 9 and 10 exhibited potent cytotoxicity against K562, Bel-7402, and A549 cell lines with IC₅₀ values less than 0.1, 0.1, and 1.0 μm, respectively.     

Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents

To search for novel nitric oxide (NO) releasing anti-tumor agents, a series of novel furoxan/oridonin hybrids were designed and synthesized. Firstly, the nitrate/nitrite levels in the cell lysates were tested by a Griess assay and the results showed that these furoxan-based NO-releasing derivatives could produce high levels of NO in vitro. Then the anti-proliferative activity of these hybrids against four human cancer cell lines was also determined, among which, 9 h exhibited the most potential anti-tumor activity with IC?? values of 1.82 μM against K562, 1.81 μM against MGC-803 and 0.86 μM against Bel-7402, respectively. Preliminary structure-activity relationship was concluded based on the experimental data obtained. These results suggested that NO-donor/natural product hybrids may provide a promising approach for the discovery of novel anti-tumor agents.     

Synthesis and anti-tumor activities of novel [1,2,4]triazolo[1,5-a]pyrimidines

A series of novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives has been designed and synthesized in order to find novel anti-tumor compounds. The structures of all the compounds were confirmed by IR, 1H-NMR, MS and elemental analysis. Their anti-tumor activities against cancer cell lines (HT-1080 and Bel-7402) were tested by the MTT method in vitro. Among them, compound 19 displayed the best anti-tumor activity with IC50 values of 12.3 microM and 6.1 microM against Bel-7402 and HT-1080 cell lines respectively.     

Synthesis and cytotoxicity studies of novel [1,2,4]triazolo[1,5-a]pyrimidine-7-amines

A series of novel N-anilino-5-methyl-2-(3-(5-(alkylaminomethyl)furan-2-yl-methylthio)propyl)-[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine derivatives were synthesized and evaluated for their in vitro cytotoxicity against two cancer cell lines, Bel-7402 and HT-1080. Compounds 9, 14, 19 and 23 possessed marked cytotoxicity, especially 23 (with IC(50) values of 15.0 microM and 7.8 microM against Bel-7402 and HT-1080 cell lines, respectively), which had emerged as lead compound. The activity was found to depend strongly on substitution pattern of the side chains at C-2 position, and 4-triflouromethylanilino substituent at C-7 position was an option for anticancer potency.     

Synthesis of novel heptaplatin derivatives and evaluation of their ability to inhibit proliferation of cancer cell lines

A series of novel heptaplatin derivatives were synthesized and evaluated for their ability to inhibit growth of two cancer cell lines: human colon carcinoma cell line HCT-8 and human hepatocarcinoma cell line Bel-7402. Majority of the synthesized compounds demonstrated superior activity against cancer cell lines compared to heptaplatin. Specifically, compounds 5a and 5b (5 µg/mL) had more pronounced efficacy against the HCT-8 cell line while 6b and 6c (0.5 µg/mL) had higher efficacy against Bel-7402 cell line.     

Studies on cytotoxic and DNA-binding properties of two ruthenium(II) complexes of a substituted phenanthroline ligand

Two chair ruthenium(II) complexes, Λ- and Δ-[Ru(bpy)₂tFMPIP]^{2 +} (bpy = bipyridyl; tFMPIP = (2′-trifluoromethylphenyl)-imidazo-[4,5-f]-[1, 10]-phenanthroline, Λ-1 and Δ-1) have been synthesized and characterized by elemental analysis, ESI-MS and ¹H-NMR. The cytotoxicity of these complexes against human hepatocarcinoma cell line Bel-7402, human intestinal adenocarcinoma cell line HCT-8, and Human lung adenocarcinoma epithelial cell line A-549 have been investigated by colorimetric MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-1H-tetrazolium bromide) assay. Both Λ-1 and Δ-1 exhibit excellent inhibitory activity against the growth of Bel-7402 and HCT-8 cells. At dosage of 5 μg/cm³, the inhibition of Λ-1 and Δ-1 against human hepatocarcinoma cell line Bel-7402 is 85 and 85%, respectively. The studies on the DNA-binding properties of these complexes with Bel-7402 cell DNA by electronic spectra and steady state emission spectra, as well as circular dichlorism spectra show that there are detectable but subtle differences between Λ-1 and Δ-1, indicating the antitumor activity of these complexes is related to their DNA-binding behaviors.     

聚乙烯胺类修饰萘酰亚胺衍生物的合成、DNA键合行为和活性研究

合成了二乙烯三胺、三乙烯四胺和四乙烯五胺等低分子量聚乙烯胺类修饰的萘酰亚胺衍生物.通过UV-Vis谱、荧光光谱、圆二色谱和热变性试验研究了合成化合物与小牛胸腺DNA的键合行为,同时通过四甲基偶氮唑蓝(MTT)染色法研究了化合物对Bel-7402(人肝癌细胞)、HL-60(白血病细胞)、A549(人肺癌细胞)和Hela(人宫颈癌细胞)等细胞株的体外抗肿瘤活性,化合物NI1对A549细胞显示良好的抑制活性,优于阳性对照顺铂.     

Platinum(II) complexes of reduced amino acid ester Schiff bases: synthesis, characterization, and antitumor activity

A series of platinum(II) complexes of reduced amino acid esters Schiff bases were synthesized as potential anticancer agents and characterized by ¹H NMR, EA, IR, and molar conductivity. These compounds were tested for their DNA interaction with salmon sperm DNA by ultraviolet spectrum and CD spectrum, and their in vitro anticancer activities have been validated against HL-60, KB, BGC-823, and Bel-7402 cell lines by MTT assay. The cytotoxicity of complexes 5d and 5f are better than cisplatin against Bel-7402 cell lines, and show a close cytotoxic effect against HL-60 cell line.     

New hydrophilic/lipophilic tetra-α-(4-carboxyphenoxy) phthalocyanine zinc-mediated photodynamic therapy inhibits the proliferation of human hepatocellular carcinoma Bel-7402 cells by triggering apoptosis and arresting cell cycle

Photodynamic therapy (PDT) is a novel and promising antitumor treatment. Phthalocyanine-mediated PDT has shown antitumor activity in some tumor cells, but the effect of new hydrophilic/lipophilic tetra-α-(4-carboxyphenoxy)phthalocyanine zinc (TαPcZn)-mediated PDT (TαPcZn-PDT) on human hepatocellular carcinoma Bel-7402 cells and underlying mechanisms have not been clarified. In the present study, therefore, the ultraviolet-visible (UV-vis) absorption spectrum and cellular localization of TαPcZn, and effect of TαPcZn-PDT on the proliferation, apoptosis, cell cycle, Bcl-2 and Fas in Bel-7402 cells were investigated by spectrophotometry, inverted microscope, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, electron microscopy, annexinV-FITC/propidium iodide double staining, DNA content and immunoblot assay, respectively. We found that an intense absorption in UV-vis absorption spectrum of TαPcZn was in the red visible region at 650-680 nm, where light penetration in tissue is efficient, that green TαPcZn localized to both plasma membrane and nuclear membrane of Bel-7402 cells, signifying that there was a selective uptake of TαPcZn in Bel-7402 cells and TαPcZn-PDT would be expected to directly damage DNA, and that TαPcZn-PDT significantly resulted in the proliferation inhibition, apoptosis induction, S cell cycle arrest, and down-regulation of Bcl-2 and Fas. Taken together, we conclude that TαPcZn-PDT inhibits the proliferation of Bel-7402 cells by triggering apoptosis and arresting the cell cycle.